Literature DB >> 21346229

Protection from RNA and DNA viruses by IL-32.

Jarod A Zepp1, Claudia A Nold-Petry, Charles A Dinarello, Marcel F Nold.   

Abstract

Several studies have documented a proinflammatory role for IL-32, which induces IL-1α, IL-1β, IL-6, TNF, and chemokines via NF-κB, p38MAPK, and AP-1. However, IL-32 also participates in the responses to infection with viruses such as HIV-1 and influenza. In this study, we explored these antiviral properties of IL-32. Vital staining assays demonstrated that low concentrations (5-10 ng/ml) of rIL-32γ protected epithelial WISH cells from vesicular stomatitis virus-induced cell death. By lactate dehydrogenase assays, treatment with IL-32γ resulted in a 3- to 4-fold decrease in viral load. Specific silencing of IL-32 revealed that the antiviral responses triggered by the synthetic analogs of ssRNA viruses (polyuridine) and dsRNA viruses (polyinosinic-polycytidylic acid) were significantly weaker (2- to 3-fold more virus) in WISH cells in the absence of IL-32. Importantly, we discovered that the polyinosinic-polycytidylic acid-induced increase in production of IFN-α in human PBMC was nearly completely abolished when IL-32 was silenced. Moreover, we observed that IL-32 antagonizes the DNA virus HSV-2 in epithelial Vero cells as well as in human umbilical cord endothelial cells, as production of HSV-2 increased 8-fold upon silencing of IL-32 (p < 0.001). Mechanistically, we found that IL-32 used the PKR-eIF-2α as well as the MxA antiviral pathways. Unexpectedly, a considerable part of the antiviral properties of IL-32 was not dependent on IFNs; specific blockade of IFN activity reduced the antiviral properties of IL-32 only moderately. In conclusion, these data suggest a central role for IL-32 in the immune response to RNA and DNA viruses, which may be exploitable for clinical use in the future.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21346229     DOI: 10.4049/jimmunol.1000081

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  19 in total

1.  An effector phenotype of CD8+ T cells at the junction epithelium during clinical quiescence of herpes simplex virus 2 infection.

Authors:  Tao Peng; Jia Zhu; Khamsone Phasouk; David M Koelle; Anna Wald; Lawrence Corey
Journal:  J Virol       Date:  2012-07-18       Impact factor: 5.103

2.  Soluble interleukin-6 receptor is elevated during influenza A virus infection and mediates the IL-6 and IL-32 inflammatory cytokine burst.

Authors:  Jun Wang; Qing Wang; Tao Han; Yong-Kui Li; Sheng-Li Zhu; Fang Ao; Jian Feng; Ming-Zhen Jing; Li Wang; Lin-Bai Ye; Ying Zhu
Journal:  Cell Mol Immunol       Date:  2014-09-01       Impact factor: 11.530

3.  IL-32 promotes angiogenesis.

Authors:  Claudia A Nold-Petry; Ina Rudloff; Yvonne Baumer; Menotti Ruvo; Daniela Marasco; Paolo Botti; Laszlo Farkas; Steven X Cho; Jarod A Zepp; Tania Azam; Hannah Dinkel; Brent E Palmer; William A Boisvert; Carlyne D Cool; Laima Taraseviciene-Stewart; Bas Heinhuis; Leo A B Joosten; Charles A Dinarello; Norbert F Voelkel; Marcel F Nold
Journal:  J Immunol       Date:  2013-12-11       Impact factor: 5.422

4.  IL-32 expression in the airway epithelial cells of patients with Mycobacterium avium complex lung disease.

Authors:  Xiyuan Bai; Alida R Ovrutsky; Marinka Kartalija; Kathryn Chmura; Amanda Kamali; Jennifer R Honda; Rebecca E Oberley-Deegan; Charles A Dinarello; James D Crapo; Ling-Yi Chang; Edward D Chan
Journal:  Int Immunol       Date:  2011-10-27       Impact factor: 4.823

5.  Interleukin 32 (IL-32) contains a typical α-helix bundle structure that resembles focal adhesion targeting region of focal adhesion kinase-1.

Authors:  Bas Heinhuis; Marije I Koenders; Wim B van den Berg; Mihai G Netea; Charles A Dinarello; Leo A B Joosten
Journal:  J Biol Chem       Date:  2011-12-27       Impact factor: 5.157

6.  Interleukin-32 isoforms: expression, interaction with interferon-regulated genes and clinical significance in chronically HIV-1-infected patients.

Authors:  Katia Monteleone; Pierluigi Di Maio; Giulia Cacciotti; Francesca Falasca; Maurizio Fraulo; Mario Falciano; Ivano Mezzaroma; Gabriella D'Ettorre; Ombretta Turriziani; Carolina Scagnolari
Journal:  Med Microbiol Immunol       Date:  2014-02-20       Impact factor: 3.402

Review 7.  Role of interleukin-32 in chronic rhinosinusitis.

Authors:  Anjeni Keswani; Robert C Kern; Robert P Schleimer; Atsushi Kato
Journal:  Curr Opin Allergy Clin Immunol       Date:  2013-02

8.  Inducible interleukin 32 (IL-32) exerts extensive antiviral function via selective stimulation of interferon λ1 (IFN-λ1).

Authors:  Yongkui Li; Jiajia Xie; Xiupeng Xu; Li Liu; Yushun Wan; Yingle Liu; Chengliang Zhu; Ying Zhu
Journal:  J Biol Chem       Date:  2013-05-31       Impact factor: 5.157

Review 9.  Novel insights into the biology of interleukin-32.

Authors:  Leo A B Joosten; Bas Heinhuis; Mihai G Netea; Charles A Dinarello
Journal:  Cell Mol Life Sci       Date:  2013-03-06       Impact factor: 9.261

10.  Therapeutic effectiveness of intratumorally delivered dendritic cells engineered to express the pro-inflammatory cytokine, interleukin (IL)-32.

Authors:  Y Qu; J L Taylor; A Bose; W J Storkus
Journal:  Cancer Gene Ther       Date:  2011-07-15       Impact factor: 5.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.